Search results
AHA 25: The OCEAN Trial
Added:
5 months ago
Video
AHA 24: The OPTION Trial
Added:
1 year ago
Video
Added:
2 years ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from…
View more
Added:
1 hour ago
Source:
Radcliffe CKM
A post hoc secondary analysis of the SOUL trial has found that once-daily oral semaglutide is associated with early and sustained improvements in multiple cardiovascular (CV) risk factors in high-risk patients with type 2 diabetes (T2D).¹ These findings help to explain the mechanisms behind the primary trial results, which showed a 14% reduction in major adverse cardiovascular events (MACE) with…
View more
Added:
5 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Added:
3 weeks ago
Source:
Radcliffe CVRM
Individuals with type 2 diabetes (T2D) face a high risk of atherosclerotic cardiovascular disease (ASCVD). The SOUL trial (NCT03914326) previously demonstrated that oral semaglutide reduced major adverse cardiovascular events (MACE).² A new post hoc secondary analysis of this trial now provides insight into the mechanisms behind this benefit, detailing the drug's association with changes in key…
View more
Added:
1 month ago
Source:
Radcliffe CVRM
A new study has found that the novel oral GLP-1 receptor agonist, orforglipron, demonstrated superior glycaemic control compared to oral semaglutide in adults with type 2 diabetes (T2D). The findings come from the ACHIEVE-3 trial, a phase 3 study published in The Lancet.¹Mechanism of ActionOrforglipron is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist designed for once-daily oral…
View more
Added:
1 month ago
Source:
Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an…
View more
Added:
5 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with…
View more
Added:
7 months ago
Presented at the European Society of Cardiology (ESC) Congress 2025, Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) examine the prevalence and challenges of stroke prevention in atrial fibrillation (AF) and after acute coronary syndrome (ACS). The faculty review current treatment guidelines, explore…
View more